Zubik S 250mg/125mg Injection
Marketer
Stenhill Labs
Salt Composition
Ceftriaxone (250mg) + Sulbactam (125mg)
Overview Zubik S 250mg/125mg Injection
Combiflox 250mg/125mg Injection, a dual-action antibiotic, combats diverse bacterial infections by hindering microbial proliferation. Administration must be overseen by a medical professional; adherence to the prescribed schedule is crucial. Complete the entire course, regardless of symptom improvement; premature cessation may compromise efficacy. Commonly reported side effects include nausea, vomiting, diarrhea, and dyspepsia. Severe or worsening side effects warrant immediate medical consultation. Allergic reactions (e.g., rash, pruritus, edema, dyspnea) necessitate prompt medical attention. Inform your physician of all current medications before commencing treatment. Pregnant or lactating individuals should consult their doctor prior to use. Alcohol consumption should be avoided due to potential additive drowsiness. While generally non-impairing, driving should be avoided if drowsiness or dizziness occurs. Adequate rest, a balanced diet, and sufficient hydration contribute to faster recovery. Monitoring via laboratory tests may be implemented to assess treatment effectiveness.
Primary Ingredients of Zubik S 250mg/125mg Injection
No text provided. Please provide the text you would like me to rephrase.
Uses of Zubik S 250mg/125mg Injection
Infections caused by bacteria
Major Benefits of Zubik S 250mg/125mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Zubik S 250mg/125mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Zubik S 250mg/125mg Injection:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
How Zubik S 250mg/125mg Injection works:
Ceftriaxone/Sulbactam 250mg/125mg Injection (Zubik S) combines the antibiotic Ceftriaxone with the beta-lactamase inhibitor Sulbactam. Ceftriaxone's mechanism involves disrupting bacterial cell wall synthesis, a process crucial for bacterial viability. Sulbactam counteracts bacterial resistance mechanisms, thereby bolstering Ceftriaxone's antibacterial effectiveness.
SAFETY ADVICE
AlcoholSAFE
Concurrent alcohol use with Zubik S 250mg/125mg Injection presents no known adverse reactions.
PregnancySAFE IF PRESCRIBED
The injectable medication Zubik S 250mg/125mg is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or no harmful consequences for the fetus; nonetheless, clinical data from human trials are scarce.
Breast feedingCAUTION
The administration of Zubik S 250mg/125mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's treatment course and until the medication is fully cleared from her system.
DrivingUNSAFE
The administration of Zubik S 250mg/125mg Injection can lead to reduced awareness, visual impairment, drowsiness, and dizziness. Driving should be avoided if such effects are experienced.
KidneyCONSULT YOUR DOCTOR
Data on Zubik S 250mg/125mg Injection use in individuals with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
For individuals with severe hepatic impairment, the administration of Zubik S 250mg/125mg Injection requires careful consideration and potential dosage modification. A physician's consultation is advised. Dosage alteration of Zubik S 250mg/125mg Injection is unnecessary for patients exhibiting mild to moderate liver dysfunction.
What if you forget to take Zubik S 250mg/125mg Injection :
Omit a Zubik S 250mg/125mg Injection dose? Seek your physician's advice.
Facts to Know About Zubik S 250mg/125mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobials |
3,018 People bought this recently